Genmab

	19/6 06:28 af transalp	Go morgen.. :)
	18/6 16:19 af gentogen	(link)
	18/6 16:18 af gentogen	Interim results show HMB-001 significantly reduces frequency of bleeding events with a favorable safety profile, supporting its potential as a novel prophylactic treatment for GT. HMB-001’s subcutaneous dosing offers a proactive alternative to reactive GT care, addressing a critical unmet need.
	18/6 16:16 af gentogen	(link)
	18/6 14:57 af E L	Hemab Therapeutics @Hemab_Tx ICYMI: Last week we announced the International Non-Proprietary Name (INN) sutacimig for HMB-001 — marking the first-ever INN for a treatment designated for Glanzmann thrombasthenia.(link)
	18/6 14:15 af E L	RITUXIMAB AND EPCORITAMAB AS FIRST-LINE THERAPY FOR PATIENTS WITH HIGH-TUMOR BURDEN FOLLICULAR LYMPHOMA: FIRST RESULTS OF A MULTICENTER PHASE II TRIAL (link) -from the 18th International Conference on Malignant Lymphoma (link)
	18/6 07:49 af E L	EHA 2025 \| How effective is epcoritamab + R-ICE in patients with R/R DLBCL who are ASCT eligible? (link)
	18/6 07:34 af E L	Epcoritamab Plus Chemoimmunotherapy Yields 87% Response Rate in R/R DLBCL; 65% Proceed to Transplant (link)
	18/6 07:29 af E L	EHA 2025 – J&J claims an extramedullary edge The company sees an improvement with a Tecvayli/Talvey combo vs either monotherapy. (link)
	18/6 07:23 af E L	Presentations & posters for EHA 2025 via (link)
	18/6 06:27 af transalp	Go morgen.. :)
	17/6 18:24 af bikube	UHA, det bliver sjovt at evaluere på. Men den enkelte patients behov må jo komme i første række.
	17/6 12:51 af E L	España lidera un estudio pionero con epcoritamab para mejorar el abordaje del linfoma B de células grandes (link) REPIFIR = Response-adaptive to Epcoritamab In FIrst Relapse
	17/6 11:20 af ProInvestorNEWS	Jyske Bank: Genmab – Positivt nyt fra Epcoritamab (link)
	16/6 17:32 af ProInvestorNEWS	Hej wisuwa...Du kan evt starte med at læse chathistorikken. :-) (link)
	16/6 15:52 af E L	EHA 2025: Genmab and AbbVie’s Epkinly outpaces BiTE rivals in r/r DLBCL trial (link)
	16/6 15:42 af Helge Larsen/PI-redaktør	Transactions in Connection with Share Buy-back Program (link)
	16/6 14:58 af wisuwa	Nå... Har været lidt fraværende i Genmab-regi. Hvad ser vi ind i nu? Hvad er kurstriggerne? Og nogle der har regnet på et EOY kursniveau? :)
	16/6 12:31 af Raun	Ja enig - det er jo vildt imponerende :-)
	16/6 11:56 af gentogen	"Lovende" er da vist en underdrivelse...
	16/6 07:29 af ProInvestorNEWS	Genmab har lovende resultater med kræftmiddel i lymfekræftform (link)
	15/6 20:03 af E L	Fixed-Duration Epcoritamab Plus Pola-R-CHP Demonstrates Durable Efficacy in First-Line DLBCL (link)
	15/6 15:38 af E L	sry that's the same one lol
	15/6 15:37 af E L	Investigational combination of first-in-class bispecifics TALVEY® and TECVAYLI® shows deep and durable responses in heavily pretreated multiple myeloma patients with extramedullary disease (link)

	15/6 15:14 af Solsen	(link) Flotte resultater på Genmab bispecific vi ser i NHL og MM. Specielt imponerede med epco i first line kombo.
	15/6 14:59 af Solsen	:-)
	15/6 14:34 af Helge Larsen/PI-redaktør	Genmab Announces Epcoritamab Investigational Combination Therapy Demonstrates High Response Rates in Patients with Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) Eligible for Autologous Stem Cell Transplantation (ASCT) (link)
	15/6 14:34 af E L	"These promising results compare favorably to other regimens in 1L and may provide higher cure rates for patients with 1L DLBCL than SOC", suggesting that further exploration is warranted.
	15/6 14:33 af E L	Lymphoma Hub @lymphomahub CONGRESS \| #EHA2025 \| PRESENTATION Daniel Kerr, @TGHCares presents updated results from the epcoritamab + pola-R-CHP cohort of the phase Ib/II EPCORE NHL-5 trial (N = 37). (link)
	15/6 14:30 af Bulder	Epco fortsætter sin sejrsgang. Det bliver stort - ad åre.
	15/6 11:37 af JKY_VH	Super og mange tak for den Budweis:-)
	15/6 11:11 af Budweis	Genmab Announces Epcoritamab Investigational Combination Therapy Demonstrates High Response Rates in Patients with Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) Eligible for Autologous Stem Cell Transplantation (ASCT)
	15/6 11:11 af Budweis	Ser lovende ud (link)
	14/6 13:52 af Helge Larsen/PI-redaktør	(Artiklen om Genmab kræver ikke abonnement)
	14/6 13:51 af Helge Larsen/PI-redaktør	Oversigt: Ny udgave af ØU Life Science – Genmab accelererer mod blockbusterstatus med Rina-S efter data (link)
	13/6 09:05 af gentogen	Thanks EL for the link 15:24 yesterday. Pure KYSO...
	12/6 15:24 af E L	Epcoritamab Improves Outcomes, HRQOL in Patients With Relapsed/Refractory Follicular Lymphoma (link) EHA 2025
	12/6 15:23 af E L	they may have, but for a relatively small value. If I remember correct, they invested $20mn and sold a part of that for +-$60mn (?) . The remainder collapsed in value...
	12/6 13:04 af Solsen	I belive Genmab still have some shares left i CureVac.
	12/6 12:50 af E L	BioNTech Announces Strategic Transaction to Acquire CureVac in Public Exchange Offer (link)
	10/6 17:00 af lahn1	Yes as 4-1BB has a history of poor tolerability, it seems logical to be able to show durable tolerability with zero or low discontinuation rates. Docetaxel having 15-20% discontinuation as SOC in 2L NSCLC.
	10/6 16:55 af E L	only Time to Treatment Discontinuation Due to AE is new. (the other was already there, the old 5. ) to me the question is more; why wasn't that there in the first place (logical measure)
	10/6 16:54 af lahn1	Sorry, jeg fik vist blandet koncentratione af acasunlimab i plasma sammen med t-cell exhaustion.
	10/6 16:45 af Solsen	Acasunlimab has a huge potential. Tahi seems very bullish. But data on limited pts until now. But if they can show high number and long responses in NSCLC in second line it could be big.
	10/6 16:44 af lahn1	De 2 nye endpoint kan vel være andet end positive, selvom jeg primært ser dem som det. Lyder plasma kontrol lidt som vi var inden på ved resultaterne af ph2, at en individuel doserings regime (timing) ift Aca koncentrationen i plasma ser ud til at kunne optimere effekten ? Discontinuation rate er vel kun forberedelse på godkendelse vs Docetaxel i 2 L og måske bedre forståelse for AE ift med mulige fremtidige kombinationer. Hvordan læse I andre de nye end points ?
	10/6 16:40 af Solsen	Yes I agree.
	10/6 16:22 af E L	the fact that they started a Melanoma trial with Acasunlimab is a strong signal i would think
	10/6 16:15 af Solsen	I have been a little cautious on Acasunlimab after Biontech left. But there is a chance that Biontech where wrong.
	10/6 16:11 af Solsen	Looks like Rina-S also are running fast :-)
	10/6 16:01 af E L	ASCO 2025 presentations via (link)